Literature DB >> 1699410

Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods.

L Seymour1, K Meyer, J Esser, A P MacPhail, A Behr, W R Bezwoda.   

Abstract

Immunocytochemical assays for progesterone receptor (PR) using monoclonal antirabbit PR antibodies (PR-ICA) and for estrogen receptor (ER) (ER-ICA) were compared with radioligand binding (dextran-coated charcoal [DCC]) methods for receptor determination in patients with breast cancer. Immunocytochemical staining for PR was exclusively nuclear in localization. In this regard, PR staining is similar to previous findings for ER; PR-ICA showed a sensitivity of 89% and specificity of 100%. ER-ICA was also 89% sensitive and similarly specific. There was good correlation between the degree and intensity of staining and quantitative binding of radioligand. Receptor-positive tumors, however, show considerable variation of immunocytochemical staining, suggesting heterogeneity of cellular PR content. The availability of an immunocytochemical assay for PR increases the discriminatory potential for these methods of receptor determination.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699410

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Analysis of estrogen and progesterone receptors on preoperative fine-needle aspirates.

Authors:  B Frigo; S Pilotti; S Zurrida; L Ermellino; A Manzari; F Rilke
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

2.  c-erb-B2 expression and response to treatment in metastatic breast cancer.

Authors:  W R Bezwoda
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

Review 3.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

4.  P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer.

Authors:  L Seymour; W R Bezwoda; R D Dansey
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

5.  Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer.

Authors:  L Seymour; W R Bezwoda
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Predicting aggressive outcome in T1N0M0 breast cancer.

Authors:  P Kronqvist; T Kuopio; M Nykänen; H Helenius; J Anttinen; P Klemi
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.